Investments
32Portfolio Exits
6Funds
1About Malaysian Life Sciences Capital Fund
The Malaysian Life Sciences Capital Fund (MLSCF) specializes in early stage investments in the areas of agriculture, industrial and healthcare biotechnology. Co-managed by Malaysian Technology Development Corporation Sdn Bhd (MTDC) and Burrill & Company, the fund was founded in late 2006 and currently has USD150 million in committed capital. MLSCF is organized to invest in Leading, Privately Held Life Science companies with Malaysia centricity and deliver on the twin objectives of superior financial results and advancing the life science eco-system in and for the country of Malaysia.
Want to inform investors similar to Malaysian Life Sciences Capital Fund about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Malaysian Life Sciences Capital Fund
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Malaysian Life Sciences Capital Fund in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Malaysian Life Sciences Capital Fund Investments
32 Investments
Malaysian Life Sciences Capital Fund has made 32 investments. Their latest investment was in Greenlight Biosciences as part of their PIPE on February 2, 2022.
Malaysian Life Sciences Capital Fund Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
2/3/2022 | PIPE | Greenlight Biosciences | $105M | No | 1 | |
6/16/2020 | Series D - IV | Greenlight Biosciences | $102M | No | 4 | |
4/4/2019 | Series C - IV | Inscripta | $20M | No | 5 | |
12/19/2018 | Series C - III | |||||
2/28/2018 | Series C |
Date | 2/3/2022 | 6/16/2020 | 4/4/2019 | 12/19/2018 | 2/28/2018 |
|---|---|---|---|---|---|
Round | PIPE | Series D - IV | Series C - IV | Series C - III | Series C |
Company | Greenlight Biosciences | Greenlight Biosciences | Inscripta | ||
Amount | $105M | $102M | $20M | ||
New? | No | No | No | ||
Co-Investors | |||||
Sources | 1 | 4 | 5 |
Malaysian Life Sciences Capital Fund Portfolio Exits
6 Portfolio Exits
Malaysian Life Sciences Capital Fund has 6 portfolio exits. Their latest portfolio exit was LanzaTech on February 09, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
2/9/2023 | Reverse Merger | 4 | |||
Date | 2/9/2023 | ||||
|---|---|---|---|---|---|
Exit | Reverse Merger | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 4 |
Malaysian Life Sciences Capital Fund Fund History
1 Fund History
Malaysian Life Sciences Capital Fund has 1 fund, including MLS Capital Fund II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
1/7/2015 | MLS Capital Fund II | $150M | 2 |
Closing Date | 1/7/2015 |
|---|---|
Fund | MLS Capital Fund II |
Fund Type | |
Status | |
Amount | $150M |
Sources | 2 |
Malaysian Life Sciences Capital Fund Team
1 Team Member
Malaysian Life Sciences Capital Fund has 1 team member, including current Chief Executive Officer, Ganesh Kishore.
Name | Work History | Title | Status |
|---|---|---|---|
Ganesh Kishore | Chief Executive Officer | Current |
Name | Ganesh Kishore |
|---|---|
Work History | |
Title | Chief Executive Officer |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
